Análise de custo do tratamento medicamentoso da artrite reumatóide

R. Monteiro, A. C. Zanini
{"title":"Análise de custo do tratamento medicamentoso da artrite reumatóide","authors":"R. Monteiro, A. C. Zanini","doi":"10.1590/S1516-93322008000100004","DOIUrl":null,"url":null,"abstract":"With the aim to compare the cost of treatment for rheumatoid arthritis therapy with desease-modifying antirheumatic drugs (DMARDs) for a 48-month period, were studied five different treatment stage based on clinical protocols recommended by the Brazilian Society of Rheumatology, and then five therapy cycles. The analytical model based on the Markov Analysis, considered chaces for the patient continue in some stages or change between them according with a positive effect on outcomes. Only direct costs were comprised in the analyzed data, like drugs, materials and tests used for monitoring these patients. The results of the model show that the stage in with metotrexato drug is used like monotherapy was cost-effective (R$ 113,900.00 for patient during 48 months), followed by refractory patient (R$ 1,554,483.43), those that use therapy triplicate followed by infleximabe drug (R$ 1,701,286.76), the metotrexato intolerant patient (R$ 2,629,919.14), and final the result from that use metotrexato and infliximabe in the beginning (R$ 9,292,879.31). The sensitivity analysis confirm this results, when alternate the efficacy of metotrexato and infliximabe.","PeriodicalId":21193,"journal":{"name":"Revista Brasileira De Ciencias Farmaceuticas","volume":"81 1","pages":"25-33"},"PeriodicalIF":0.0000,"publicationDate":"2008-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"11","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Brasileira De Ciencias Farmaceuticas","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/S1516-93322008000100004","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 11

Abstract

With the aim to compare the cost of treatment for rheumatoid arthritis therapy with desease-modifying antirheumatic drugs (DMARDs) for a 48-month period, were studied five different treatment stage based on clinical protocols recommended by the Brazilian Society of Rheumatology, and then five therapy cycles. The analytical model based on the Markov Analysis, considered chaces for the patient continue in some stages or change between them according with a positive effect on outcomes. Only direct costs were comprised in the analyzed data, like drugs, materials and tests used for monitoring these patients. The results of the model show that the stage in with metotrexato drug is used like monotherapy was cost-effective (R$ 113,900.00 for patient during 48 months), followed by refractory patient (R$ 1,554,483.43), those that use therapy triplicate followed by infleximabe drug (R$ 1,701,286.76), the metotrexato intolerant patient (R$ 2,629,919.14), and final the result from that use metotrexato and infliximabe in the beginning (R$ 9,292,879.31). The sensitivity analysis confirm this results, when alternate the efficacy of metotrexato and infliximabe.
类风湿性关节炎药物治疗的成本分析
为了比较类风湿关节炎治疗与疾病改善抗风湿药物(DMARDs) 48个月期间的治疗成本,根据巴西风湿病学会推荐的临床方案研究了5个不同的治疗阶段,然后研究了5个治疗周期。基于马尔可夫分析的分析模型,考虑了患者在某些阶段继续或在它们之间根据对结果的积极影响而变化的机会。所分析的数据中只包括直接成本,如用于监测这些患者的药物、材料和测试。模型结果显示,使用甲氨喋呤单药治疗的患者在48个月内具有成本效益(113,900.00雷亚尔),其次是难治性患者(1,554,483.43雷亚尔),其次是使用三次治疗的患者(1,701,286.76雷亚尔),其次是甲氨喋呤不耐受患者(2,629,919.14雷亚尔),最后是开始使用甲氨喋呤和英利昔贝的结果(9,292,879.31雷亚尔)。当交替使用甲氨喋呤和英菲昔单抗时,敏感性分析证实了这一结果。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信